Synonyms: ASP-1517 | ASP1517 | Evrenzo® | FG-4592 | FG4592
roxadustat is an approved drug (EMA (2021))
Compound class:
Synthetic organic
Comment: Roxadustat is a compound which inhibits hypoxia inducible factor prolyl hydroxylase (HIF-PH) activity. HIF-PH inhibitors are being investigated as novel therapies for anemia, especially anemia caused by chronic kindney disease (CKD) [2]. It is hoped that HIF-PH inhibitors will provide a more effective alternative to the use of erythropoetin replacement therapy plus iron supplementation in CKD patients.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Bouchie A. (2013)
First-in-class anemia drug takes aim at Amgen's dominion. Nat Biotechnol, 31 (11): 948-9. [PMID:24213751] |
2. Forristal CE, Levesque JP. (2014)
Targeting the hypoxia-sensing pathway in clinical hematology. Stem Cells Transl Med, 3 (2): 135-40. [PMID:24371328] |
3. Joharapurkar AA, Pandya VB, Patel VJ, Desai RC, Jain MR. (2018)
Prolyl Hydroxylase Inhibitors: A Breakthrough in the Therapy of Anemia Associated with Chronic Diseases. J Med Chem, 61 (16): 6964-6982. [PMID:29712435] |
4. Liu C, Jursa T, Aschner M, Smith DR, Mukhopadhyay S. (2021)
Up-regulation of the manganese transporter SLC30A10 by hypoxia-inducible factors defines a homeostatic response to manganese toxicity. Proc Natl Acad Sci U S A, 118 (35). DOI: 10.1073/pnas.2107673118 [PMID:34446561] |